AVENGER 500
Adding the metabolism drug devimistat to FOLFIRINOX did not help people with metastatic pancreatic cancer live longer.
Overview
AVENGER 500 was an open-label phase 3 trial in previously untreated metastatic pancreatic adenocarcinoma comparing modified FOLFIRINOX with devimistat against modified FOLFIRINOX alone. The primary endpoint was overall survival. The trial did not show a survival benefit, and response rates were similar between arms, closing the pancreatic programme for devimistat.
Similar pages
not linked directly; found by shared links- CompanyCornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)
- TrialA Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- TrialPREOPANC-1 / PREOPANC-2
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- TrialLAPIS
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- TrialPRODIGE 24 / CCTG PA6
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- TrialNAPOLI 3
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- TrialStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- IdeaRAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.